Skip to main content
OpenTrials
Completed

NCT Number: NCT00231283

NEXUS Study for the Treatment of de Novo Native Coronary Artery Lesions

The objective of this study is to evaluate the effectiveness and safety of the CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-Wire (OTW) Stent Delivery System (SDS) in patients with de novo native coronary artery lesions.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Texas Heart Institute

Houston, Texas, 77030, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or non-pregnant female patients 18 years of age
  • Diagnosis of angina pectoris as defined by Canadian Cardiovascular Society Classification (CCS I, II, III, IV) OR unstable angina pectoris (Braunwald Classification B&C, I-II) OR patients with documented silent ischemia;
  • Treatment of a single de novo target lesion in a major native coronary artery;
  • Target lesion is 2.5 mm and 3.5 mm in diameter (visual estimate);
  • Target lesion is 30mm in length (visual estimate);
  • Target lesion stenosis is > 50% and < 100% (visual estimate);

Exclusion criteria

  • Patient has experienced a Q-wave or non-Q-wave myocardial infarction with documented total CK > 2 times normal within the preceding 24 hours and the CK and CK-MB enzymes remain above normal at the time of treatment;
  • Has unstable angina classified as Braunwald III B or C, or is having a peri-infarction angina;
  • Significant (> 50%) stenoses proximal or distal to the target lesion that might require revascularization or impede runoff;
  • Documented Left ventricular ejection fraction 25%;
  • Totally occluded vessel (TIMI 0 level);
  • Impaired renal function (creatinine > 3.0 mg/dl) at the time of treatment;

Treatment and study plan

CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)

Device

CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System

Primary outcomes

  1. Percentage of Participants Who Achieved Procedure Success From Post-procedure to Hospital Discharge

    Time frame: From post-procedure up to hospital discharge

    Procedure Success is defined as the final residual diameter stenosis < 50 percent by Quantitative Coronary Angiography (QCA) using any percutaneous method, without the occurrence of death, Myocardial Infarction (MI), or repeat revascularization of the target lesion

Secondary outcomes

  1. Percentage of Participants Who Experienced Any Major Adverse Cardiac Events From Post-procedure to 30 Days Later

    Time frame: From post-procedure up to 30 days

    Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).

  2. Percentage of Participants Who Experienced Any Major Adverse Cardiac Events From Post-procedure to Hospital Discharge

    Time frame: From post-procedure up to hospital discharge

    Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).

  3. Percentage of Participants Who Experienced Any Major Adverse Cardiac Events From Post-procedure to 12 Months Later

    Time frame: From post-procedure up to 12 months

    Major Adverse Cardiac Events (MACE) consists of death, Myocardial Infarction (Q-wave and Non Q-wave), emergent Coronary Artery Bypass Graft (CABG) or Target Lesion Revascularization (TLR).

Sponsors and collaborators

Lead sponsor

Cordis US Corp.

Industry

Registry information

Official study title

A Multicenter, Non-Randomized Study of the CYPHER NxT Sirolimus-Eluting Coronary Stent on BX SONIC OVER-THE-WIRE (OTW) Stent Delivery System(SDS)for the Treatment of de Novo Native Coronary Artery Lesions

Important dates

Study start
2004
Study completion
2005
First posted
Oct 4, 2005
Registry last updated
Apr 20, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.